Lipocine Inc. has appointed Michael J. Grissinger to its Board of Directors, effective August 3, 2026. Grissinger brings over two decades of experience from Johnson & Johnson, where he held senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. He currently serves on the boards of Aprea Therapeutics and Adicet Bio. Lipocine Chairman Dana Ono stated that Grissinger's dealmaking experience will be invaluable as the company advances its pipeline and pursues partnerships. Grissinger noted the company's innovative oral delivery technology and its portfolio of commercial and late-stage clinical assets.
Lipocine IncAppointment of experienced M&A executive to board, expected to aid partnerships and pipeline advancement.
Adicet Bio Inc
Aprea Therapeutics Inc
Johnson & Johnson